Literature DB >> 17201701

Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy.

Erik Hessen1, Morten I Lossius, Ivar Reinvang, Leif Gjerstad.   

Abstract

PURPOSE: All major antiepileptic drugs (AEDs) have been reported to be associated with cognitive side effects. Uncertainty exists regarding the degree of cognitive effects, primarily because many studies do not adhere to basic standards of methodology and design. The aim of this study was to assess the effect of discontinuation of AEDs in patients receiving monotherapy on measures of attention, reaction time, and speed of information processing.
METHODS: The 150 subjects who had been seizure free>2 years on drug monotherapy went through a randomized, double-blind, placebo-controlled study. Each patient was included for 12 months or until seizure relapse. Cognitive function was assessed with the California Computerized Assessment Package at baseline and 7 months after discontinuation.
RESULTS: The major finding in this study is that discontinuation of major AEDs significantly improved performance on tests that require complex cognitive processing under time pressure. The difference in speed of cognitive processing between the two groups on these tasks was between 24 to 43 ms. Simple tasks of attention and reaction time revealed no significant differences between the discontinuation group and the nondiscontinuation group. Most of the subjects in the study were medicated with carbamazepine (CBZ) and valproate (VPA). The outcome of discontinuation of CBZ was similar to the outcome for the total study population, whereas withdrawal of VPA revealed only a nonsignificant tendency in the same direction.
CONCLUSIONS: The results suggest that seizure-free epilepsy patients receiving monotherapy can obtain improvement in cognitive function if they discontinue AED treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201701     DOI: 10.1111/j.1528-1167.2006.00805.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  14 in total

1.  The cognitive impact of antiepileptic drugs.

Authors:  Clare M Eddy; Hugh E Rickards; Andrea E Cavanna
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

2.  Absence semiologies.

Authors:  Warren T Blume
Journal:  Epilepsy Curr       Date:  2009 Jul-Aug       Impact factor: 7.500

3.  Antiepileptic drug effects on subjective and objective cognition.

Authors:  Robert J Quon; Morgan T Mazanec; Samantha S Schmidt; Angeline S Andrew; Robert M Roth; Todd A MacKenzie; Martha Sajatovic; Tanya Spruill; Barbara C Jobst
Journal:  Epilepsy Behav       Date:  2020-01-29       Impact factor: 2.937

Review 4.  Carbamazepine versus valproate monotherapy for epilepsy.

Authors:  A G Marson; P R Williamson; J L Hutton; H E Clough; D W Chadwick
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Cognitive outcomes in children who present with a first unprovoked seizure.

Authors:  Yoshimi Sogawa; David Masur; Christine O'Dell; Solomon L Moshe; Shlomo Shinnar
Journal:  Epilepsia       Date:  2010-09-24       Impact factor: 5.864

6.  Thalamofrontal circuitry and executive dysfunction in recent-onset juvenile myoclonic epilepsy.

Authors:  Dalin T Pulsipher; Michael Seidenberg; Leslie Guidotti; Victoria N Tuchscherer; Jared Morton; Raj D Sheth; Bruce Hermann
Journal:  Epilepsia       Date:  2009-01-17       Impact factor: 5.864

Review 7.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

8.  Attention impairment in temporal lobe epilepsy: a neurophysiological approach via analysis of the P300 wave.

Authors:  Perrine Bocquillon; Kathy Dujardin; Nacim Betrouni; Valérian Phalempin; Elise Houdayer; Jean-Louis Bourriez; Philippe Derambure; William Szurhaj
Journal:  Hum Brain Mapp       Date:  2009-07       Impact factor: 5.038

9.  Valerenic acid and Valeriana officinalis extracts delay onset of Pentylenetetrazole (PTZ)-Induced seizures in adult Danio rerio (Zebrafish).

Authors:  Bianca A Torres-Hernández; Lisa M Del Valle-Mojica; José G Ortíz
Journal:  BMC Complement Altern Med       Date:  2015-07-14       Impact factor: 3.659

10.  A patient with medication-resistant epilepsy featuring psychosensorial and psychotic symptoms presenting with significant functional improvement on psychotherapeutic treatment: a case report.

Authors:  Luigi De Benedictis; Alexandre Dumais; Luc Nicole; Christine Grou; Alain D Lesage
Journal:  J Med Case Rep       Date:  2013-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.